The 24 references in paper Olga Shakhmatova O., О. Шахматова О. (2018) “СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ ДАБИГАТРАНА ИДАРУЦИЗУМАБ: ЧТО ИЗВЕСТНО НА СЕГОДНЯШНИЙ ДЕНЬ // IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE” / spz:neicon:aterotromboz:y:2018:i:2:p:147-157

1
Connolly S.J., ezekowitz M.D., et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.
(check this in PDF content)
2
Devereaux P.J., Duceppe e., Guyatt G., et al., on behalf of the MANAGe Investigators. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGe): an international, randomised, placebo-controlled trial. Lancet. 2018; 391: 2325-34.
(check this in PDF content)
3
инструкция по применению к препарату Праксбайнд. Patient Information Leaflet for Praxbind https://www.rlsnet.ru/tn_index_id_96610. htm.
(check this in PDF content)
4
Glund S., Stangier J., Schmohl M. et al. Safety, tolerability,and eficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, doubleblind phase 1 trial. Lancet. 2015; 386: 680690.
(check this in PDF content)
5
Schiele F., van Ryn J., Canada K. et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2014; 121(18): 3554-3562.
(check this in PDF content)
6
Becker R.C. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J. Thromb. Thrombolysis. 2016; 41: 273-278.
(check this in PDF content)
7
Simon A., Domanovits H., Ay C., Sengoelge G., Levy J.H., Spiel A.O. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J. Thromb. Haemost. 2017; 15: 1317 – 21.
(check this in PDF content)
8
Steele A.P., Lee J.A., Dager W.A. Incomplete dabigatran reversal with dabigatran. Clin Toxicol (Phila). 2018; 56: 216–8.
(check this in PDF content)
9
Novak Je., Alamiri K., Yee J. Dabigatran Reversal in a Patient with end-Stage Liver Disease and Acute Kidney Injury. Am J Kidney Dis. 2017; 71(1): 137-141.
(check this in PDF content)
10
Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 2010; 49(4): 259-268.
(check this in PDF content)
11
Glund S., Moschetti V., Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb. Haemost. 2015; 113: 943-951.
(check this in PDF content)
12
Glund S., Stangier J., Schmohl M. et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014; 124: 344 (abstract).
(check this in PDF content)
13
Pollack C.V. Jr., Reilly P.A., van Ryn J., et al. Idarucizumab for dabigatran reversal – Full cohort analysis. N. Engl. J. Med. 2017; 377: 431–41.
(check this in PDF content)
14
Alonso A., Bengtson L.G., MacLehose R.F., et al. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke. 2014 Aug; 45(8): 2286-91. doi: 10.1161/ STROKeAHA.114.006016. epub 2014 Jul 3.
(check this in PDF content)
15
Alonso А., Bengtson L.G.S, MacLehose R.F., et al. Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin. Stroke. 2014; 45: 2286–2291.
(check this in PDF content)
16
Vosko M.R., Bocksrucker С., Drwiła R., et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran treated. J. Thromb. Thrombolysis. 2 017 ; 43: 306–317.
(check this in PDF content)
17
Goriacko P., Yaghdjian V., Koleilat I., et al. The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series. P T. 2017 Nov; 42(11): 699703.
(check this in PDF content)
18
Tsai L.-K., Lin H.-J., Chua S.-K., et al. RealWorld experience with Idarucizumab to Reverse Anticoagulant effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan. Journal of Stroke and Cerebrovascular Diseases. 2018; 27(2): e27–e33.
(check this in PDF content)
19
Shiroshita A., Nakashima K., Tanaka Y., et al. Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report. Journal of Thrombosis and Thrombolysis. 2018; 46: 271–273.
(check this in PDF content)
20
Giannandrea D., Caponi C., Mengoni A., et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J. Neurol. Neurosurg. Psychiatry. 2018; 0: 1–5. doi:10.1136/jnnp-2018-318658.
(check this in PDF content)
21
Шахматова О.О. Специфические антидоты к новым пероральным антикоагулянтам. Атеротромбоз. 2016; 1: 81-94. [Shakhmatova OO. Specific reversal agents for new oral anticoagulants. Aterotromboz. 2016; 1: 81-94.] (In Russ).
(check this in PDF content)
22
Levy J.H., Ageno W., Chan N.C., Crowther M., Verhamme P., Weitz J.I. for the Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2016; 14: 623-627.
(check this in PDF content)
23
Kirchhof P., Benussi S., Kotecha D., et al. 2016 eSC Guidelines for the management of atrial fibrillation developed in collaboration with eACTS. European Heart Journal. 2016; 37(38): 2893–2962. https://doi. org/10.1093/eurheartj/ehw210.
(check this in PDF content)
24
Steffel J., Verhamme P., Potpara T.S., et al. The 2018 european Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018 April 21; 39(16): 1330-1393.
(check this in PDF content)